Fatma Uçar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fatma Uçar has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Ali Yalçındağ
Department of Biochemistry, Ankara Training and Research Hospital, University of Health Sciences, Ankara 06230, Turkey
3 shared publications - Gulfer Ozturk
Department of Biochemistry, Ministry of Health Diskapi Yildirim Beyazit Education and Research Hospital, Ankara, Turkey
3 shared publications - Gonul Erden
Department of Clinical Biochemistry, Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey
2 shared publications Abdullah Ercan Arzuhal
Department of Clinical Biochemistry, Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey
1 shared publication- Ahmet Ozsoy
Department of Biochemistry, University of Health Sciences, Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey
1 shared publication - Ahmet Yalçın Üstün
Faculty of Medicine, Azerbaijan Medical University, Baku, Azerbaijan
1 shared publication
Latest Publications
- 1 November 2026
- Published by Bayrakol Medical Publishing in Journal of Clinical and Analytical Medicine
- Vol. 17 (11) , 1177-1181
Six Sigma-based assessment of critical cardiac biomarkers in the emergency laboratory
Aim Emergency laboratories require rapid, reliable test results to ensure patient safety, particularly for critical cardiac parameters. Six Sigma methodology offers an objective approach to assessing analytical performance by integrating precision, bias, and total allowable error. This study aimed to evaluate the analytical performance of high-sensitivity troponin T (Hs-TnT), creatine kinase-MB (CK-MB), and N-terminal pro–B-type natriuretic peptide (NT-proBNP) utilizing sigma metrics on two automated analyzers. Methods This study was conducted in the Clinical Biochemistry Laboratory of Ankara Etlik City Hospital using internal quality control (IQC) and external quality control (EQC) data collected between July and December 2024. Sigma metrics were calculated for Hs-TnT, CK-MB, and NT-proBNP on two Roche Cobas 8000 e801 analyzers. CV%, bias%, and TEa values (Clinical Laboratory Improvement Amendments [CLIA] 2025) were used to compute sigma. Quality goal index (QGI) was used to further explore sources of analytical error when sigma values were below 3. Results Hs-TnT demonstrated excellent performance (σ ≥ 6) on both analyzers at Level 2, while NT-proBNP showed excellent performance on Analyzer A at Level 1. No analyte exhibited poor performance (σ < 3) on either analyzer. CK-MB displayed adequate to good performance depending on the analyzer and control level. QGI results supported that none of the biomarkers showed error patterns indicative of critical analytical problems. Conclusion Hs-TnT, NT-proBNP, and CK-MB demonstrated acceptable-to-excellent analytical performance according to Sigma metrics, confirming their reliability in emergency laboratory settings. Sigma methodology is a fundamental approach for evaluating analytical performance, especially for critical tests. Ongoing assessment and verification ensure analytical quality and reliable results for clinical decision-making.
- 1 November 2026
- Published by Bayrakol Medical Publishing in Journal of Clinical and Analytical Medicine
- Vol. 17 (11) , 1177-1181
Six Sigma-based assessment of critical cardiac biomarkers in the emergency laboratory
Aim Emergency laboratories require rapid, reliable test results to ensure patient safety, particularly for critical cardiac parameters. Six Sigma methodology offers an objective approach to assessing analytical performance by integrating precision, bias, and total allowable error. This study aimed to evaluate the analytical performance of high-sensitivity troponin T (Hs-TnT), creatine kinase-MB (CK-MB), and N-terminal pro–B-type natriuretic peptide (NT-proBNP) utilizing sigma metrics on two automated analyzers. Methods This study was conducted in the Clinical Biochemistry Laboratory of Ankara Etlik City Hospital using internal quality control (IQC) and external quality control (EQC) data collected between July and December 2024. Sigma metrics were calculated for Hs-TnT, CK-MB, and NT-proBNP on two Roche Cobas 8000 e801 analyzers. CV%, bias%, and TEa values (Clinical Laboratory Improvement Amendments [CLIA] 2025) were used to compute sigma. Quality goal index (QGI) was used to further explore sources of analytical error when sigma values were below 3. Results Hs-TnT demonstrated excellent performance (σ ≥ 6) on both analyzers at Level 2, while NT-proBNP showed excellent performance on Analyzer A at Level 1. No analyte exhibited poor performance (σ < 3) on either analyzer. CK-MB displayed adequate to good performance depending on the analyzer and control level. QGI results supported that none of the biomarkers showed error patterns indicative of critical analytical problems. Conclusion Hs-TnT, NT-proBNP, and CK-MB demonstrated acceptable-to-excellent analytical performance according to Sigma metrics, confirming their reliability in emergency laboratory settings. Sigma methodology is a fundamental approach for evaluating analytical performance, especially for critical tests. Ongoing assessment and verification ensure analytical quality and reliable results for clinical decision-making.
- Open Access
- 19 May 2026
- Published by Springer Nature in BMC Gastroenterology
- Vol. 26 (1)
Association between iron status and inflammation markers with GDF15 and BMP6 in inflammatory bowel disease: a single center cross-sectional study
Inflammatory bowel diseases (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), are chronic disorders with relapsing and remitting dis
- 19 May 2026
- Published by Springer Nature in BMC Gastroenterology
- Vol. 26 (1)
Open AccessAssociation between iron status and inflammation markers with GDF15 and BMP6 in inflammatory bowel disease: a single center cross-sectional study
Inflammatory bowel diseases (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), are chronic disorders with relapsing and remitting dis
- Open Access
- 18 June 2025
- Published by Journal of Medicine and Palliative Care in Journal of Medicine and Palliative Care
- Vol. 6 (3) , 258-264
Association of serum HIF-1α levels with mortality and ICU admission in hospitalized patients with SARS-CoV-2 infection: a prospective cohort study
Aims: SARS-CoV-2 infection can trigger a dysregulated immune response, including cytokine storm syndrome (CSS), which exacerbates respiratory failure through heightened pro-inflammatory mediators and hypoxemia. Hypoxia-inducible factor-1α (HIF-1α) orchestrates cellular adaptation to hypoxia by shifting metabolism toward glycolysis. Prior studies present varying evidence regarding HIF-1α’s role in acute inflammatory states. The purpose of this study was to investigate the role of hypoxia inducible factor 1a (HIF-1a) in predicting mortality, ward and intensive care unit (ICU) admission requirements. Methods: The study was performed as a single center prospective study in a tertiary center. Hospitalized patients with at least one positive nasopharyngeal COVID-19 reverse transcription-polymerase chain reaction test were included in the study. White blood cell count, thrombocyte count, lactate levels, fibrinogen, D-dimer, brain natriuretic peptide (BNP), C-reactive protein (CRP), procalcitonin, ferritin, interleukin 6 (IL-6) troponin, partial oxygen, and partial carbon dioxide pressure from arterial blood gas sampling were recorded. Results: Of 127 screened, 80 participants completed the study (mean age 66.1±17.2 years; 54% male). Thirty-day mortality was 21.3% (n=17). Median BNP (529 vs. 1,957 pg/ml), ferritin (256 vs. 598.5 ng/ml), and IL-6 (14 vs. 101 pg/ml) were significantly higher in non-survivors (p=0.043, 0.003, and 0.001, respectively). Survivors exhibited lower median HIF-1α (0.85 vs. 1.20 ng/ml), but this difference was not statistically significant (p>0.05). Subgroup analyses by CURB-65 and ICU status similarly revealed no significant HIF-1α differences. HIF-1α did not correlate with any inflammatory markers. HIF-1α levels at admission did not significantly predict ICU care or mortality. This may reflect HIF-1α’s pro- and anti-inflammatory roles and variability in sampling timing relative to disease onset. Current literature suggests both protective and detrimental HIF-1α effects, complicating its prognostic utility. Conclusion: Admission HIF-1α alone does not predict clinical outcomes in hospitalized COVID-19. Studies incorporating serial measurements and baseline controls are warranted to evaluate HIF-1α’s involvement in COVID-19 pathophysiology.
- 18 June 2025
- Published by Journal of Medicine and Palliative Care in Journal of Medicine and Palliative Care
- Vol. 6 (3) , 258-264
Open AccessAssociation of serum HIF-1α levels with mortality and ICU admission in hospitalized patients with SARS-CoV-2 infection: a prospective cohort study
Aims: SARS-CoV-2 infection can trigger a dysregulated immune response, including cytokine storm syndrome (CSS), which exacerbates respiratory failure through heightened pro-inflammatory mediators and hypoxemia. Hypoxia-inducible factor-1α (HIF-1α) orchestrates cellular adaptation to hypoxia by shifting metabolism toward glycolysis. Prior studies present varying evidence regarding HIF-1α’s role in acute inflammatory states. The purpose of this study was to investigate the role of hypoxia inducible factor 1a (HIF-1a) in predicting mortality, ward and intensive care unit (ICU) admission requirements. Methods: The study was performed as a single center prospective study in a tertiary center. Hospitalized patients with at least one positive nasopharyngeal COVID-19 reverse transcription-polymerase chain reaction test were included in the study. White blood cell count, thrombocyte count, lactate levels, fibrinogen, D-dimer, brain natriuretic peptide (BNP), C-reactive protein (CRP), procalcitonin, ferritin, interleukin 6 (IL-6) troponin, partial oxygen, and partial carbon dioxide pressure from arterial blood gas sampling were recorded. Results: Of 127 screened, 80 participants completed the study (mean age 66.1±17.2 years; 54% male). Thirty-day mortality was 21.3% (n=17). Median BNP (529 vs. 1,957 pg/ml), ferritin (256 vs. 598.5 ng/ml), and IL-6 (14 vs. 101 pg/ml) were significantly higher in non-survivors (p=0.043, 0.003, and 0.001, respectively). Survivors exhibited lower median HIF-1α (0.85 vs. 1.20 ng/ml), but this difference was not statistically significant (p>0.05). Subgroup analyses by CURB-65 and ICU status similarly revealed no significant HIF-1α differences. HIF-1α did not correlate with any inflammatory markers. HIF-1α levels at admission did not significantly predict ICU care or mortality. This may reflect HIF-1α’s pro- and anti-inflammatory roles and variability in sampling timing relative to disease onset. Current literature suggests both protective and detrimental HIF-1α effects, complicating its prognostic utility. Conclusion: Admission HIF-1α alone does not predict clinical outcomes in hospitalized COVID-19. Studies incorporating serial measurements and baseline controls are warranted to evaluate HIF-1α’s involvement in COVID-19 pathophysiology.
- 30 August 2022
- Published by Caleo in Turkish Society of Clinical Biochemistry
- Vol. 20 (2) , 083-090
The Need for Assay Harmonization: Carbohydrate Antigen 19-9 (CA 19-9) Assay Example
Amaç: CA 19-9, yüksek riskli kişilerde pankreas, safra kanalı ve kolon kanserlerinin tespiti ve takibinde diğer testlerin tamamlayıcısı olarak yaygın kullanılan bir biyobelirteçtir. CA 19-9 testinin farklı yöntemlerle ölçüm sonuçları arasında uyumsuzluklar bulunabilmektedir. Bu çalışmanın amacı CA 19-9 testinin harmonizasyon problemini ortaya koymaktır. Gereç ve Yöntemler: Randox Uluslararası Kalite Değerlendirme Programı tarafından sağlanan 2018 yılına ait dış kalite değerlendirme programına göre, üç farklı seviyede CA 19-9 içeren dış kalite kontrol serum örneklerinin sonuçları değerlendirildi. Abbott Architect, Beckman Access DXI600/800, Roche Cobas 6000/8000 ve Siemens Advia Centaur XP/XPT/Classic cihazlarına ait sonuçlar karşılaştırıldı. Bulgular: Dış kalite kontrol programından elde edilen verilere göre, aynı numune için farklı cihazlardan elde edilen CA 19-9 test sonuçları arasında bir uyum tespit edilememiştir. Dört sistemin her birine ait peer grup ortalamaları ve laboratuvarlararası CV’ler oldukça farklılık göstermektedir. Genel olarak, en yüksek peer grup ortalama değerleri Abbott Architect sistemi, bunu takiben Siemens Centaur XP/XPT/Classic sisteminden ve en düşük peer grup ortalamaları ise Roche Cobas sisteminden elde edilmiştir. Laboratuvarlararası % CV 4.5-10.1 arasında değişen geniş bir aralık göstermektedir. Sonuç: Bulgularımıza göre, dört farklı sistem kullanılarak elde edilen CA 19-9 sonuçlarının harmonizasyonunun henüz sağlanamadığı görülmüştür. Farklı üreticilere ait kitlerle ölçülen CA 19-9 konsantrasyonları sistematik farklılıklar(farklı antikor kullanımı vb.) nedeniyle varyasyon gösterebilir. Sonuç olarak, CA 19-9 düzeyini ölçmede kullanılan kit/yöntemin laboratuvar sonuç raporunda belirtilmesinin faydalı olacağını düşünüyoruz.
- 30 August 2022
- Published by Caleo in Turkish Society of Clinical Biochemistry
- Vol. 20 (2) , 083-090
The Need for Assay Harmonization: Carbohydrate Antigen 19-9 (CA 19-9) Assay Example
Amaç: CA 19-9, yüksek riskli kişilerde pankreas, safra kanalı ve kolon kanserlerinin tespiti ve takibinde diğer testlerin tamamlayıcısı olarak yaygın kullanılan bir biyobelirteçtir. CA 19-9 testinin farklı yöntemlerle ölçüm sonuçları arasında uyumsuzluklar bulunabilmektedir. Bu çalışmanın amacı CA 19-9 testinin harmonizasyon problemini ortaya koymaktır. Gereç ve Yöntemler: Randox Uluslararası Kalite Değerlendirme Programı tarafından sağlanan 2018 yılına ait dış kalite değerlendirme programına göre, üç farklı seviyede CA 19-9 içeren dış kalite kontrol serum örneklerinin sonuçları değerlendirildi. Abbott Architect, Beckman Access DXI600/800, Roche Cobas 6000/8000 ve Siemens Advia Centaur XP/XPT/Classic cihazlarına ait sonuçlar karşılaştırıldı. Bulgular: Dış kalite kontrol programından elde edilen verilere göre, aynı numune için farklı cihazlardan elde edilen CA 19-9 test sonuçları arasında bir uyum tespit edilememiştir. Dört sistemin her birine ait peer grup ortalamaları ve laboratuvarlararası CV’ler oldukça farklılık göstermektedir. Genel olarak, en yüksek peer grup ortalama değerleri Abbott Architect sistemi, bunu takiben Siemens Centaur XP/XPT/Classic sisteminden ve en düşük peer grup ortalamaları ise Roche Cobas sisteminden elde edilmiştir. Laboratuvarlararası % CV 4.5-10.1 arasında değişen geniş bir aralık göstermektedir. Sonuç: Bulgularımıza göre, dört farklı sistem kullanılarak elde edilen CA 19-9 sonuçlarının harmonizasyonunun henüz sağlanamadığı görülmüştür. Farklı üreticilere ait kitlerle ölçülen CA 19-9 konsantrasyonları sistematik farklılıklar(farklı antikor kullanımı vb.) nedeniyle varyasyon gösterebilir. Sonuç olarak, CA 19-9 düzeyini ölçmede kullanılan kit/yöntemin laboratuvar sonuç raporunda belirtilmesinin faydalı olacağını düşünüyoruz.
- Open Access
- 11 May 2022
- Published by Walter de Gruyter GmbH in Turkish Journal of Biochemistry
- Vol. 47 (5) , 557-563
Verification of enzymatic ethanol analysis method and method comparison with headspace gas chromatography
Objectives: This study aimed to verify the enzymatic ethanol analysis method and compare the technique with headspace gas chromatography (HS/GC). Methods: The limit of the blank, limit of detection, and limit of quantification, precision, linearity, and accuracy of the enzymatic process were evaluated based on the data obtained. In addition, a method comparison was made between the enzymatic method and the HS/GC analysis method. Results: It was seen that the enzymatic method was linear in the range of 14–450 mg/dL, the coefficient of variation and bias values ranged between 0.5–1.09% and 4.52–9.78%, respectively. The quantitative accuracy was 2.13% and 2.23% at concentrations of 41.16 and 95.82 mg/dL, respectively. When the regression analysis was performed between the results obtained using the enzymatic alcohol dehydrogenase (ADH) and HS/GC methods, y=0.966x + 2.084 linear relationship formula and regression coefficient of r 2 =0.9987, it was found that it showed a good agreement at a confidence interval of 5%. Conclusions: The findings showed that the enzymatic method had good linearity, excellent precision, and a high correlation with the higher-order comparator method, the HS/GC method, in the ethanol analysis.
- 11 May 2022
- Published by Walter de Gruyter GmbH in Turkish Journal of Biochemistry
- Vol. 47 (5) , 557-563
Open AccessVerification of enzymatic ethanol analysis method and method comparison with headspace gas chromatography
Objectives: This study aimed to verify the enzymatic ethanol analysis method and compare the technique with headspace gas chromatography (HS/GC). Methods: The limit of the blank, limit of detection, and limit of quantification, precision, linearity, and accuracy of the enzymatic process were evaluated based on the data obtained. In addition, a method comparison was made between the enzymatic method and the HS/GC analysis method. Results: It was seen that the enzymatic method was linear in the range of 14–450 mg/dL, the coefficient of variation and bias values ranged between 0.5–1.09% and 4.52–9.78%, respectively. The quantitative accuracy was 2.13% and 2.23% at concentrations of 41.16 and 95.82 mg/dL, respectively. When the regression analysis was performed between the results obtained using the enzymatic alcohol dehydrogenase (ADH) and HS/GC methods, y=0.966x + 2.084 linear relationship formula and regression coefficient of r 2 =0.9987, it was found that it showed a good agreement at a confidence interval of 5%. Conclusions: The findings showed that the enzymatic method had good linearity, excellent precision, and a high correlation with the higher-order comparator method, the HS/GC method, in the ethanol analysis.
- 22 October 2021
- Published by Pera Yayıncılık Hizmetleri in Yeni Üroloji Dergisi
- Vol. 16 (3) , 221-227
Diagnostic efficiency of miR-21 and miR-34a serum levels in malign and benign prostate diseases
Objective: In this study aimed to determine the diagnostic efficiency of miR-21 and miR-34a serum levels in the discrimination of benign prostatic hyperplasia, chronic prostatitis, and prostate cancer. Materials and Methods: Blood samples were taken from 70 patients (25 benign prostatic hyperplasias, 10 chronic prostatitides, and 35 prostate cancer) who underwent prostate needle biopsy. After obtaining serum under suitable conditions, RNA isolation, cDNA synthesis, and qRT-PCR analysis were performed using Qiagen brand kits on Rotor-Gene® Q (Qiagen, Germany) device. -∆Ct values were calculated using RNU6 as a reference gene for normalization. -∆Ct values were used in all statistical calculations. Results: It was observed that miR-21 serum levels were upregulated in chronic prostatitis and cancer groups compared to benign prostatic hyperplasia and the difference between the groups was statistically significant (p = 0.021 and p = 0.001, respectively). The specificity and sensitivity of miR-21 and miR-21/miR-34a combination was calculated as 56% and 86%; 84% and 71% in discriminating benign prostatic hyperplasia and prostate cancer groups, respectively. Conclusion: In this study, it has been shown that miR-21 and miR-21/miR-34a combination has diagnostic performance that can be a biomarker candidate in diagnosing prostate cancer. In addition, the presence of a gradual increase in chronic prostatitis and prostate cancer at miR-21 levels compared to benign prostatic hyperplasia suggests that inflammation and cancer transformation processes taking place at the molecular level are also reflected in the circulating microRNA profile. Keywords: Prostate cancer, Prostatitis, Benign prostatic hyperplasia, MicroRNA, Diagnostic efficiency
- 22 October 2021
- Published by Pera Yayıncılık Hizmetleri in Yeni Üroloji Dergisi
- Vol. 16 (3) , 221-227
Diagnostic efficiency of miR-21 and miR-34a serum levels in malign and benign prostate diseases
Objective: In this study aimed to determine the diagnostic efficiency of miR-21 and miR-34a serum levels in the discrimination of benign prostatic hyperplasia, chronic prostatitis, and prostate cancer. Materials and Methods: Blood samples were taken from 70 patients (25 benign prostatic hyperplasias, 10 chronic prostatitides, and 35 prostate cancer) who underwent prostate needle biopsy. After obtaining serum under suitable conditions, RNA isolation, cDNA synthesis, and qRT-PCR analysis were performed using Qiagen brand kits on Rotor-Gene® Q (Qiagen, Germany) device. -∆Ct values were calculated using RNU6 as a reference gene for normalization. -∆Ct values were used in all statistical calculations. Results: It was observed that miR-21 serum levels were upregulated in chronic prostatitis and cancer groups compared to benign prostatic hyperplasia and the difference between the groups was statistically significant (p = 0.021 and p = 0.001, respectively). The specificity and sensitivity of miR-21 and miR-21/miR-34a combination was calculated as 56% and 86%; 84% and 71% in discriminating benign prostatic hyperplasia and prostate cancer groups, respectively. Conclusion: In this study, it has been shown that miR-21 and miR-21/miR-34a combination has diagnostic performance that can be a biomarker candidate in diagnosing prostate cancer. In addition, the presence of a gradual increase in chronic prostatitis and prostate cancer at miR-21 levels compared to benign prostatic hyperplasia suggests that inflammation and cancer transformation processes taking place at the molecular level are also reflected in the circulating microRNA profile. Keywords: Prostate cancer, Prostatitis, Benign prostatic hyperplasia, MicroRNA, Diagnostic efficiency
- Open Access
- 3 September 2021
- Published by Hacettepe University - Medical School in Acta Medica
- p. 1-6
Analytical Process Evaluation of Biochemistry Laboratory by Using Six Sigma Method
Objectives: The primary purpose of medical laboratories is to provide the most accurate results appropriate to the patient's medical condition. Therefore, the reliability of each laboratory must be scientifically tested. Approximately 10% of laboratory errors occur in the analytical phase. In this study, we aimed to evaluate analytical process performances of 14 routinely assayed parameters according to six sigma methodology. Materials and Methods: Mean, standard deviation and coefficient of variation were calculated from internal quality control data for three months from 14 routinely assayed parameters (albumin, alanine aminotransferase, aspartate aminotransferase, chloride, creatinine, glucose, HDL cholesterol, lactate dehydrogenase, potassium, total cholesterol, total protein, sodium, triglyceride and urea) in the laboratory (Roche Cobas c501). Bias was calculated using external quality control values for same months. Total error was also calculated. Acceptable total error was determined according to the Clinical Laboratory Improvement Amendments and Turkey criteria. Sigma values were calculated and divided into four groups; as 6 world-class performance. Results: According to the Clinical Laboratory Improvement Amendments and Turkey sigma assessment, first levels of chloride, total cholesterol, glucose and urea performance were unacceptable. Moreover according to the Clinical Laboratory Improvement Amendments sigma assessment, first levels of albumin, creatinine, total protein; and both levels of sodium, chloride and urea were unacceptable. Other tests were found to be suited for purpose, acceptable or world-class performance. Conclusions: Sigma measurements should be routinely performed in laboratories for evaluating the analytical period performance of the laboratory. That will increase its quality via regulatory preventive actions. Our study allowed us to see and improve our measurement quality by determining the three-month periodic performance of our laboratory tests.
- 3 September 2021
- Published by Hacettepe University - Medical School in Acta Medica
- p. 1-6
Open AccessAnalytical Process Evaluation of Biochemistry Laboratory by Using Six Sigma Method
Objectives: The primary purpose of medical laboratories is to provide the most accurate results appropriate to the patient's medical condition. Therefore, the reliability of each laboratory must be scientifically tested. Approximately 10% of laboratory errors occur in the analytical phase. In this study, we aimed to evaluate analytical process performances of 14 routinely assayed parameters according to six sigma methodology. Materials and Methods: Mean, standard deviation and coefficient of variation were calculated from internal quality control data for three months from 14 routinely assayed parameters (albumin, alanine aminotransferase, aspartate aminotransferase, chloride, creatinine, glucose, HDL cholesterol, lactate dehydrogenase, potassium, total cholesterol, total protein, sodium, triglyceride and urea) in the laboratory (Roche Cobas c501). Bias was calculated using external quality control values for same months. Total error was also calculated. Acceptable total error was determined according to the Clinical Laboratory Improvement Amendments and Turkey criteria. Sigma values were calculated and divided into four groups; as 6 world-class performance. Results: According to the Clinical Laboratory Improvement Amendments and Turkey sigma assessment, first levels of chloride, total cholesterol, glucose and urea performance were unacceptable. Moreover according to the Clinical Laboratory Improvement Amendments sigma assessment, first levels of albumin, creatinine, total protein; and both levels of sodium, chloride and urea were unacceptable. Other tests were found to be suited for purpose, acceptable or world-class performance. Conclusions: Sigma measurements should be routinely performed in laboratories for evaluating the analytical period performance of the laboratory. That will increase its quality via regulatory preventive actions. Our study allowed us to see and improve our measurement quality by determining the three-month periodic performance of our laboratory tests.
- 1 October 2020
- Published by Wiley in The Clinical Respiratory Journal
- Vol. 14 (10) , 965-972
Relationship between right ventricular dilatation and blood copeptin levels in patients with acute pulmonary embolism
Purpose: In this study, we aimed to investigate the importance of copeptin in the diagnosis of acute pulmonary embolism, detection of right ventricular dilatation and clinical severity and prognosis of pulmonary embolism. Materials and Methods: In the study three groups were created; Group 1: Pulmonary embolism patients with right ventricular dilatation in echocardiography, Group 2: Pulmonary embolism patients without right ventricular dilatation in echocardiography, Group 3: Healthy people. Five mL of venous blood was collected for the measurement of serum copeptin from the patients and control group. D-dimer and troponin were studied with routine blood samples. Complaints, symptom and physical examination findings, tomography and echocardiography results, laboratory results of patients and treatments they received were recorded for the statistical analysis. Results: Copeptin levels of acute pulmonary embolism patients were significantly higher than healthy individuals (P < 0.001). Copeptin values of Group 1 patients were significantly higher than Group 2 patients and Group 3 patients (P < 0.001). There was a statistically significant difference the levels of copeptin, D-dimer and troponin between patients with right ventricular dilatation and patients without right ventricular dilatation (P < 0.05). AUC value in detecting right ventricular dilatation of copeptin was found to be 0.82, while specificity was 83.3% and sensitivity was 69.6%. Copeptin, D-dimer and troponin levels of patients with increased pulmonary artery pressure were statistically significantly higher than patients with normal pulmonary artery pressure (P < 0.05). Conclusion: Copeptin can be used in the diagnosis of acute pulmonary embolism and in the detection of right ventricular dilatation in pulmonary embolism.
- 1 October 2020
- Published by Wiley in The Clinical Respiratory Journal
- Vol. 14 (10) , 965-972
Relationship between right ventricular dilatation and blood copeptin levels in patients with acute pulmonary embolism
Purpose: In this study, we aimed to investigate the importance of copeptin in the diagnosis of acute pulmonary embolism, detection of right ventricular dilatation and clinical severity and prognosis of pulmonary embolism. Materials and Methods: In the study three groups were created; Group 1: Pulmonary embolism patients with right ventricular dilatation in echocardiography, Group 2: Pulmonary embolism patients without right ventricular dilatation in echocardiography, Group 3: Healthy people. Five mL of venous blood was collected for the measurement of serum copeptin from the patients and control group. D-dimer and troponin were studied with routine blood samples. Complaints, symptom and physical examination findings, tomography and echocardiography results, laboratory results of patients and treatments they received were recorded for the statistical analysis. Results: Copeptin levels of acute pulmonary embolism patients were significantly higher than healthy individuals (P < 0.001). Copeptin values of Group 1 patients were significantly higher than Group 2 patients and Group 3 patients (P < 0.001). There was a statistically significant difference the levels of copeptin, D-dimer and troponin between patients with right ventricular dilatation and patients without right ventricular dilatation (P < 0.05). AUC value in detecting right ventricular dilatation of copeptin was found to be 0.82, while specificity was 83.3% and sensitivity was 69.6%. Copeptin, D-dimer and troponin levels of patients with increased pulmonary artery pressure were statistically significantly higher than patients with normal pulmonary artery pressure (P < 0.05). Conclusion: Copeptin can be used in the diagnosis of acute pulmonary embolism and in the detection of right ventricular dilatation in pulmonary embolism.
- Open Access
- 6 April 2020
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 44 (2) , 312-315
Adiponectin levels decrease independently of body mass index and diabetes type after the normalization of hyperglycemia
Background/aim: Acute hyperglycemia is generally a frequently encountered condition in the emergency department (ED), because it is seen as a complication of diabetes mellitus (DM). In this study, we aimed to detect the change in adiponectin levels during acute hyperglycemic states and after normalization of blood glucose with insulin treatment. Materials and methods: Forty-eight patients over the age of 18 years who were admitted to the ED with acute hyperglycemia were included in the study. Serum samples were taken from patients on admission and 6 h after the normalization of blood glucose with insulin treatment, and adiponectin levels were measured in both samples. Results: There were 21 female and 27 male patients with a median age of 58.7 +/- 18 years. All patients' blood glucose levels were normalized with insulin treatment according to international recommendations. Serum adiponectin levels decreased significantly after the normalization of blood glucose in the whole group. Adiponectin levels decreased from 28.9 +/- 16.5 to 12.1 +/- 10.9 mu g/mL (P < 0.0001) in the whole group. This decrease was independent of diabetes type and body mass index. Conclusion: Normalization of blood glucose in patients with hyperglycemia caused a decrease in adiponectin levels, independent of diabetes type and/or body weight in an acute emergency setting. Inhibited upregulation of adiponectin secretion and/or blunted suppressive effect of insulin due to hyperglycemia or exogenous insulin administration may have caused the decrease in adiponectin levels.
- 6 April 2020
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 44 (2) , 312-315
Open AccessAdiponectin levels decrease independently of body mass index and diabetes type after the normalization of hyperglycemia
Background/aim: Acute hyperglycemia is generally a frequently encountered condition in the emergency department (ED), because it is seen as a complication of diabetes mellitus (DM). In this study, we aimed to detect the change in adiponectin levels during acute hyperglycemic states and after normalization of blood glucose with insulin treatment. Materials and methods: Forty-eight patients over the age of 18 years who were admitted to the ED with acute hyperglycemia were included in the study. Serum samples were taken from patients on admission and 6 h after the normalization of blood glucose with insulin treatment, and adiponectin levels were measured in both samples. Results: There were 21 female and 27 male patients with a median age of 58.7 +/- 18 years. All patients' blood glucose levels were normalized with insulin treatment according to international recommendations. Serum adiponectin levels decreased significantly after the normalization of blood glucose in the whole group. Adiponectin levels decreased from 28.9 +/- 16.5 to 12.1 +/- 10.9 mu g/mL (P < 0.0001) in the whole group. This decrease was independent of diabetes type and body mass index. Conclusion: Normalization of blood glucose in patients with hyperglycemia caused a decrease in adiponectin levels, independent of diabetes type and/or body weight in an acute emergency setting. Inhibited upregulation of adiponectin secretion and/or blunted suppressive effect of insulin due to hyperglycemia or exogenous insulin administration may have caused the decrease in adiponectin levels.
- Open Access
- 13 September 2014
- Published by Ondokuzmayis University, Faculty of Medicine in Journal of Experimental and Clinical Medicine
- Vol. 31 (2) , 77-80
Evaluation of serum vitamin D levels in elderly patients with subclinical hypothyroidism
Evaluation of serum vitamin D levels in elderly patients with subclinical hypothyroidism
- 13 September 2014
- Published by Ondokuzmayis University, Faculty of Medicine in Journal of Experimental and Clinical Medicine
- Vol. 31 (2) , 77-80
Open AccessEvaluation of serum vitamin D levels in elderly patients with subclinical hypothyroidism
Evaluation of serum vitamin D levels in elderly patients with subclinical hypothyroidism